中华实验和临床病毒学杂志
中華實驗和臨床病毒學雜誌
중화실험화림상병독학잡지
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL VIROLOGY
2010年
6期
470-472
,共3页
洪晓绿%曹红%赵方%潘兴飞%张卡%徐启桓%赵志新%李刚
洪曉綠%曹紅%趙方%潘興飛%張卡%徐啟桓%趙誌新%李剛
홍효록%조홍%조방%반흥비%장잡%서계환%조지신%리강
RNA%基因多态性%肝炎病毒%等位基因
RNA%基因多態性%肝炎病毒%等位基因
RNA%기인다태성%간염병독%등위기인
RNA%Genes%Hepacivirus%Alleles
目的 探讨miR-196a-2 SNP位点rs11614913与慢性丙型肝炎患者对长效干扰素联合利巴韦林治疗疗效的相关性.方法 选择接受聚乙二醇干扰素α-2a(Peg-IFN-α-2a)或α-2b(PegIFN-α-2b)联合利巴韦林(RBV)抗病毒治疗的慢性丙型肝炎患者共139例,其中持续病毒学应答(SVR)组82例,无病毒学应答(NVR)或复发组57例,采集静脉血并进行DNA提取,采用聚合酶链式反应-限制性内切酶长度多态性(PCR-RFLP)方法 对miR-196a-2进行SNP分型,组间差异进行分析比较.结果 位于miR-196a-2 rs11614913位点的CT基因型与TT基因型两组间比较差异具有统计学意义[P=0.006,A值=3.5(1.402-8.737)],CC基因型与TT基因型在两组间比较差异有统计学意义[P值=0.011,A值=4.000(1.330-12.031)].T等位基因与C等位基因频率在两组间比较差异有统计学意义[P=0.008,A值=1.926(1.185-3.131)].结论 位于miR-196a-2基因区rs11614913位点的多态性与慢性丙型肝炎患者抗病毒疗效具有相关性,T等位基因或TT基因型与SVR相关,而C等位基因或CC基因型与NVR或复发相关.
目的 探討miR-196a-2 SNP位點rs11614913與慢性丙型肝炎患者對長效榦擾素聯閤利巴韋林治療療效的相關性.方法 選擇接受聚乙二醇榦擾素α-2a(Peg-IFN-α-2a)或α-2b(PegIFN-α-2b)聯閤利巴韋林(RBV)抗病毒治療的慢性丙型肝炎患者共139例,其中持續病毒學應答(SVR)組82例,無病毒學應答(NVR)或複髮組57例,採集靜脈血併進行DNA提取,採用聚閤酶鏈式反應-限製性內切酶長度多態性(PCR-RFLP)方法 對miR-196a-2進行SNP分型,組間差異進行分析比較.結果 位于miR-196a-2 rs11614913位點的CT基因型與TT基因型兩組間比較差異具有統計學意義[P=0.006,A值=3.5(1.402-8.737)],CC基因型與TT基因型在兩組間比較差異有統計學意義[P值=0.011,A值=4.000(1.330-12.031)].T等位基因與C等位基因頻率在兩組間比較差異有統計學意義[P=0.008,A值=1.926(1.185-3.131)].結論 位于miR-196a-2基因區rs11614913位點的多態性與慢性丙型肝炎患者抗病毒療效具有相關性,T等位基因或TT基因型與SVR相關,而C等位基因或CC基因型與NVR或複髮相關.
목적 탐토miR-196a-2 SNP위점rs11614913여만성병형간염환자대장효간우소연합리파위림치료료효적상관성.방법 선택접수취을이순간우소α-2a(Peg-IFN-α-2a)혹α-2b(PegIFN-α-2b)연합리파위림(RBV)항병독치료적만성병형간염환자공139례,기중지속병독학응답(SVR)조82례,무병독학응답(NVR)혹복발조57례,채집정맥혈병진행DNA제취,채용취합매련식반응-한제성내절매장도다태성(PCR-RFLP)방법 대miR-196a-2진행SNP분형,조간차이진행분석비교.결과 위우miR-196a-2 rs11614913위점적CT기인형여TT기인형량조간비교차이구유통계학의의[P=0.006,A치=3.5(1.402-8.737)],CC기인형여TT기인형재량조간비교차이유통계학의의[P치=0.011,A치=4.000(1.330-12.031)].T등위기인여C등위기인빈솔재량조간비교차이유통계학의의[P=0.008,A치=1.926(1.185-3.131)].결론 위우miR-196a-2기인구rs11614913위점적다태성여만성병형간염환자항병독료효구유상관성,T등위기인혹TT기인형여SVR상관,이C등위기인혹CC기인형여NVR혹복발상관.
Objective To investigate the relationship between the SNP rs11614913 on miR196a-2 gene and the treatment effects of Peg-IFN-α plus Ribavirin on chronic hepatitis C patients. Methods The total 139 patients of chronic hepatitis C infection who received the treatment of Peg-IFN-α-2a or Peg-IFN-α-2b plus Ribavirin were enrolled in this study. The patients were divided into two groups: sustained virological response(SVR) ( n = 82 ) group and non virological response ( NVR ) or recurrence ( n = 57 )group. Blood samples were collected and chromosomal DNA was extracted. The miR-196a-2 polymorphism was determined with the method of polymerase chain reaction (PCR)-restriction fragment length polymorphism(RFLP). Results In our study, there was statistically association between miR-196a-2polymorphism and the antiviral therapy efficacy of hepatitis C patients. There was statistically significance in the CT genotype and the TT genotype of m iR-196a-2 between the two groups [P = 0. 009, A = 2. 924( 1. 285-6. 652)]. There was statistically significance in the CC genotype and the TT genotype between the two groups [P = 0. 036, A = 3.091 ( 1. 052 - 9. 078 )]. There was statistically significance in the C allele and the T allele between the two groups [P =0.036, A =3.091(1.052 -9.078)]. Conclusion These findings suggested that the rs11614913 SNP in miR - 196a-2 be associated with the antiviral therapy efficacy of hepatitis C patients, and the TT genotype or T alleles be associated with the SVR while the CC genotype or C allele could be related to the NVR or recurrence.
